Ideaya Biosciences Inc share price logo

Ideaya Biosciences Inc Share Price

NASDAQ: IDYA

Mid Cap

$30.73

+0.03

(+0.10%)

as on

Ideaya Biosciences Inc Stock Performance

as on April 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $29.88
    $30.89
    downward going graph

    2.77%

    Downside

    0.52%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $16.82
    $39.28
    downward going graph

    45.27%

    Downside

    27.82%

    Upside

    downward going graph

Ideaya Biosciences Inc share price movements today

Previous Close
$30.70
Open
$30.40
Volume
534.9K
Day's Low - High
$29.88 - $30.89
52 Week Low - High
$16.82 - $39.28

Ideaya Biosciences Inc Historical Returns

1 Month Return
+ 0.89 %
3 Month Return
-11.54 %
1 Year Return
+ 61.74 %
3 Year Return
+ 65.57 %
5 Year Return
+ 46.96 %

Ideaya Biosciences Inc Stock Fundamentals & Key Indicators

Check Ideaya Biosciences Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.7B

EPS (TTM)

-3.9758

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-156.6M

Revenue (TTM)

218.7M

Profit Margin

-51.99%

Return On Equity TTM

-10.92%

Ideaya Biosciences Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ideaya Biosciences Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Ideaya Biosciences Inc image
Ideaya Biosciences Inc
BUY$2.7B46.96%NA-51.99%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$40.8B116.23%131.78.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.5B99.64%28.132.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.4BNA121.785.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.5B52.82%18.1131.41%

Stock Returns calculator for Ideaya Biosciences Inc Stock including INR - Dollar returns

The Ideaya Biosciences Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Ideaya Biosciences Inc investment value today

Current value as on today

₹1,78,938

Returns

₹78,938

(+78.94%)

Returns from Ideaya Biosciences Inc Stock

₹61,737 (+61.74%)

Dollar Impact

₹17,202 (+17.2%)

Analyst Recommendation on Ideaya Biosciences Inc Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for Ideaya Biosciences Inc. Average target price of $52.81

Ideaya Biosciences Inc Share Price Target

Get share price movements and forecasts by analysts on Ideaya Biosciences Inc.

What analysts predicted

41.81%UPSIDE

Target Price

$52.81

Current Price

$30.73

Analyzed by

17 Analysts

Target

$52.81

Ideaya Biosciences Inc target price $52.81, a slight upside of 41.81% compared to current price of $30.73. According to 17 analysts rating.

Ideaya Biosciences Inc Stock’s Investor Sentiment and Interest

Search interest for Ideaya Biosciences Inc Stock has increased by 207% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:207% versus previous 30 day period

Ideaya Biosciences Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
8
3
-
-
-
7
-
-
207
10
Gross Profit
7
2
-1
-1
-1
6
-1
-1
206
9
Operating Income
-33
-41
-51
-64
-66
-144
-84
-88
108
-94
EBITDA
-26
-32
-51
-51
-50
-129
-71
-76
120
-93
Interest Expense
-
25
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
0
1
1
1
1
Income Before Tax
-27
-33
-39
-52
-51
-130
-72
-77
119
-83
Income Tax Expense
-1
5
-1
-1
-
-
-
-
-
-
Net Income
-27
-33
-39
-52
-51
-130
-72
-77
119
-83
Net Profit Margin
-341.38%
-865.54%
0.00%
0.00%
0.00%
-1861.60%
0.00%
0.00%
57.37%
-765.66%

Ideaya Biosciences Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
19
27
50
23
7
218
Gross Profit
0
0
-1
19
27
50
19
3
214
Operating Income
-14
-36
-44
-35
-50
-62
-134
-326
-159
EBITDA
-11
-33
-43
-33
-48
-60
-108
-270
-154
Interest Expense
-
-
-
0
0
3
21
-
-
Depreciation
0
0
1
1
1
2
4
3
4
Income Before Tax
-11
-34
-41
-34
-49
-58
-112
-274
-113
Income Tax Expense
0
2
-3
-2
-2
-3
3
-
-
Net Income
-11
-34
-38
-32
-47
-54
-112
-274
-113
Net Profit Margin
0.00%
0.00%
0.00%
-165.14%
-170.11%
-107.61%
-483.05%
-3921.10%
-51.99%

Ideaya Biosciences Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-33
-39
-52
-51
-130
-72
-77
119
-83
Operating Cash Flow
-23
-43
-32
-49
-121
-60
-62
142
-90
Investing Cash Flow
-111
-
68
-20
-197
79
45
41
-97
Financing Cash Flow
140
349
39
286
2
26
1
0
2
Change in Cash
5
-48
74
217
-316
45
-15
184
-186

Ideaya Biosciences Inc Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-34
-41
-34
-49
-58
-112
-274
-113
Operating Cash Flow
-27
-39
55
-55
-87
-115
-247
-71
Investing Cash Flow
-63
2
-146
-69
-33
-158
-502
69
Financing Cash Flow
105
50
128
145
97
362
677
29
Change in Cash
14
13
37
20
-23
89
-72
28

Global Institutional Holdings in Ideaya Biosciences Inc

Funds
Holdings
T. Rowe Price Associates, Inc.
1.26%
Logos Global Management LP
2.56%
Citadel Advisors Llc
1.5%
BlackRock Inc
9.26%
Morgan Stanley - Brokerage Accounts
1.8%
See all

Ideaya Biosciences Inc News & Key Events

    Insights on Ideaya Biosciences Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, IDYA has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, IDYA has outperformed top 5 stocks with highest market-cap in its industry

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 207.83M → 10.87M (in $), with an average decrease of 94.8% per quarter

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 7 days, IDYA stock has moved down by -8.5%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 119.24M → -83.27M (in $), with an average decrease of 169.8% per quarter

    About Ideaya Biosciences Inc

    IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incor
    OrganisationIdeaya Biosciences Inc
    Headquarters5000 Shoreline Court, South San Francisco, CA, United States, 94080
    IndustryBiotechnology
    CEOMr. Yujiro S. Hata
    E-voting on sharesClick here to vote

    Key Management of Ideaya Biosciences Inc

    Name

    Title

    Mr. Douglas B. Snyder

    Chief Legal Officer

    Ms. Francine Zelaya

    Senior VP & Head of Human Resources

    Mr. Andres Ruiz Briseno CPA

    Chief Accounting Officer

    Dr. Darrin M. Beaupre M.D., Ph.D.

    Chief Medical Officer

    Mr. Stuart C. Dorman

    Chief Commercial Officer

    Dr. Joshua Bleharski Ph.D.

    Chief Financial Officer

    Dr. Paul A. Barsanti Ph.D.

    Chief Technology Officer

    Mr. Yujiro S. Hata

    Founder, President, CEO & Director

    Dr. Michael A. White Ph.D.

    Chief Scientific Officer

    Mr. Mick O'Quigley

    Senior Vice President of Medical Writing & Project Management

    FAQs

    What is Ideaya Biosciences Inc share price today?

    Ideaya Biosciences Inc share price today is $30.73 as on at the close of the market. Ideaya Biosciences Inc share today touched a day high of $30.89 and a low of $29.88.

    What is the 52 week high and 52 week low for Ideaya Biosciences Inc share?

    Ideaya Biosciences Inc share touched a 52 week high of $39.28 on and a 52 week low of $16.82 on . Ideaya Biosciences Inc stock price today i.e. is closed at $30.73,which is 21.77% down from its 52 week high and 82.70% up from its 52 week low.

    What is Ideaya Biosciences Inc's market capitalisation today?

    Ideaya Biosciences Inc market capitalisation is $0.00T as on .

    How to invest in Ideaya Biosciences Inc Stock (IDYA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Ideaya Biosciences Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ideaya Biosciences Inc Shares that will get you 0.0488 shares as per Ideaya Biosciences Inc share price of $30.73 per share as on April 25, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Ideaya Biosciences Inc Stock (IDYA) from India?

    Indian investors can start investing in Ideaya Biosciences Inc (IDYA) shares with as little as ₹94.22 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹942.20 in Ideaya Biosciences Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Ideaya Biosciences Inc share’s latest price of $30.73 as on April 25, 2026 at 1:29 am IST, you will get 0.3254 shares of Ideaya Biosciences Inc. Learn more about fractional shares .

    What are the returns that Ideaya Biosciences Inc has given to Indian investors in the last 5 years?

    Ideaya Biosciences Inc stock has given 46.96% share price returns and 25.89% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?